Vinoxin 30 mg extended release (vincamine) – 60 tabs
alternative to the hard-to-get Oxybral
by Acino, Switzerland / Ukraine
Vincamine (main ingredient) has a selective vasoregulatory effect on cerebral circulation, contributing to the adaptation of cerebral circulation to the metabolic needs of the brain. The drug improves brain metabolism by enhancing glucose oxidation, thereby increasing energy production and helping to increase the overall activity of the body.
Vincamine increases the supply of oxygen to neurons in a state of hypoxia. The drug reduces and stabilizes the peripheral resistance of cerebral vessels. It has been proven that vincamine does not have biological, hematological toxicity and side effects on the kidneys and liver. Pharmacokinetics. Rapidly absorbed in the digestive tract, T ½ – 60-90 min, plasma protein binding – 64%. Vincamine is completely metabolized in the liver, only 4-6% is excreted in the urine unchanged.
Vinoxin MV to normalize and adapt cerebral circulation in accordance with the metabolic needs of the brain.
To improve, regulate and maintain brain functions in such conditions:
- memory impairment;
- impaired concentration;
- diabetic angiopathy;
- atherosclerotic lesion of cerebral vessels;
- post-traumatic craniocerebral disorders;
- after acute cerebrovascular accident;
- cerebral disorders after cerebral ischemia;
- hypertensive encephalopathy;
- impaired hearing and vision of vascular origin;
- disorientation in space and time, emotional disorders, which are the consequences of various mental disorders
Vinoxin MV adults appoint inside 1 tablet 2 times a day. The duration of treatment is determined by the doctor individually, depending on the course of the disease. Contraindications hypersensitivity to any component of the drug. Brain tumor (or diseases that cause increased intracranial pressure), convulsive disorders, acute stroke, abnormal heart rhythm, severe electrolyte disorders (hypokalemia or hypocalcemia).
mental disorders : a slight increase in mental activity. From the nervous system : headache, dizziness. From the side of the cardiovascular system : prolongation of the QT interval , flutter -ventricular fibrillation (torsade des pointes). From the digestive system : nausea, heartburn, diarrhea, constipation, dry mouth. From the immune system : hypersensitivity reactions, including angioedema. From the skin and subcutaneous tissue : erythema, itching, allergic dermatitis, urticaria, papular rash. special instructions do not exceed recommended doses.
Use with caution in patients with myocardial infarction, heart disease or heart failure. In such cases, low initial doses are used, clinical observation is carried out, and ECG monitoring is carried out. Do not use if the QT interval is prolonged as there is a risk of ventricular arrhythmias. With prolonged use of vincamine, liver function should be monitored. The drug contains lactose, so it should not be prescribed to patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome. Use during pregnancy or lactation.
Children. Vinoxin MB tablets are not recommended for use in children. The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Vincamine may affect the reaction rate when driving vehicles or working with other mechanisms. Interactions co-administration with drugs that can provoke torsade des pointes should be avoided. If this is not possible, careful clinical and ECG monitoring is recommended. Interactions specific to vinca alkaloid. Quinupristin and dalfopristin are strong inhibitors of cytochrome P450 ZA4 and can increase the concentration of vinca alkaloid when used together. Patients should be monitored for adverse symptoms of vinca alkaloid and the dose of vincamine should be adjusted accordingly. A possible mechanism for the interaction between itraconazole and vinca alkaloid is cytochrome P450 inhibition by itraconazole. Itraconazole can also inhibit the P-glycoprotein pump responsible for the elimination of vinca alkaloid. Therefore, when itraconazole and vincamine are co-administered, patients should be carefully monitored. Overdose in case of overdose, careful clinical observation, ECG monitoring, symptomatic treatment and maintenance of vital body functions are recommended. There is no specific antidote. Storage conditions in original packaging at a temperature not exceeding 25 ° C.